Prescription Medicine for Men Over 40: A Complete Clinical Guide

Why Men Over 40 Need a Different Prescription Framework

After 40, the hormonal and metabolic environment shifts in ways that make single-condition thinking inadequate. Testosterone tends to decline. Visceral fat accumulates more easily. Blood pressure and glucose tolerance often worsen. These processes interact: low testosterone is associated with a higher rate of metabolic syndrome in the endocrinology literature, though the exact magnitude of that association varies across studies and should be checked against the primary paper rather than quoted as a fixed multiplier (JCEM).

That overlap means a prescriber treating one condition should routinely reassess whether adjacent conditions need attention too.

The Five Core Clinical Domains

The prescription field for men over 40 organizes into five domains:

1. Hormonal optimization (testosterone and related hormonal therapies)
2. Metabolic and weight management (GLP-1 receptor agonists, metformin)
3. Cardiovascular risk reduction (statins, antihypertensives, aspirin)
4. Sexual health (PDE5 inhibitors, injection therapy)
5. Androgenic conditions (benign prostatic hyperplasia, male-pattern hair loss)

Each section below covers one domain, with typical dosing and the monitoring that generally goes with it. None of this substitutes for a clinician's individualized dosing decision.

Testosterone Replacement Therapy (TRT)

The American Urological Association's guideline describes testosterone therapy as appropriate for men with symptomatic hypogonadism, defined as a total serum testosterone below 300 ng/dL confirmed on two morning blood draws, in men who also have a relevant symptom such as low libido, fatigue, depressed mood, or reduced lean mass (AUA Guideline). Labs alone, without symptoms, are generally not sufficient grounds to start treatment.

Available Formulations

What the Evidence Shows

The Testosterone Trials (TTrials), a coordinated set of placebo-controlled trials in men 65 and older, found that TRT improved sexual function, mood, and bone mineral density, with mixed results on physical performance (NEJM, 2016). Body-composition changes were modest but statistically significant; the exact magnitude varies by sub-study and should be confirmed against the specific trial report before citing a precise figure.

A 2023 meta-analysis in JAMA Network Open pooling dozens of randomized trials found that TRT reduced fat mass and improved measures of insulin sensitivity in hypogonadal men (JAMA Network Open, 2023). The pooled effect size on fat mass was modest; readers who need the exact number for a specific claim should pull it from the source article rather than this summary.

Monitoring on TRT

Labs at baseline, then commonly at 3 and 6 months, then annually:

• Total and free testosterone (target ranges are individualized, typically mid-normal on trough or mid-cycle testing)
• Hematocrit (dose reduction or pause is generally considered above roughly 54%)
• PSA (a rise that is unusually rapid over 12 months warrants urologic evaluation)
• Lipid panel and CBC

Men who want to preserve fertility should discuss this with their prescriber before starting TRT. Exogenous testosterone suppresses endogenous LH and FSH, which can lead to testicular atrophy and impaired sperm production; hCG co-administration or nasal testosterone are sometimes used as alternatives when fertility is a priority.

GLP-1 Receptor Agonists for Weight and Metabolic Health

Obesity in men over 40 is not only a cosmetic concern. Visceral fat converts testosterone to estrogen through aromatization, raises cardiovascular risk, and worsens insulin resistance. GLP-1 receptor agonists address several of these mechanisms at once.

Semaglutide (Ozempic / Wegovy)

In the STEP-1 trial (N=1,961), once-weekly subcutaneous semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo (NEJM, 2021).

The SELECT trial (N=17,604), which enrolled adults with established cardiovascular disease but without diabetes, found that semaglutide 2.4 mg reduced major adverse cardiovascular events by about 20% over a median follow-up of just under three years (NEJM, 2023). Men over 40 with a prior heart attack or stroke are among the clearer candidates for this indication.

Tirzepatide (Mounjaro / Zepbound)

Tirzepatide acts on both GLP-1 and GIP receptors. The SURMOUNT-1 trial (N=2,539) showed roughly 21% mean weight reduction at the 15 mg dose at 72 weeks (NEJM, 2022).

In men with type 2 diabetes, the SURPASS-2 trial (N=1,879) compared tirzepatide 15 mg with semaglutide 1 mg and found tirzepatide produced a meaningfully larger reduction in HbA1c; the exact difference between the two arms should be confirmed against the published trial data before it is quoted to a decimal point (NEJM, 2021).

Dosing and Side Effect Profile

Gradual dose increases with both medications help minimize nausea. Semaglutide dosing begins at 0.25 mg weekly and increases over approximately four months until reaching the standard 2.4 mg weekly dose. Tirzepatide starts at 2.5 mg weekly with increases every four weeks, capping at 15 mg weekly. Side effects most often involve the gastrointestinal tract, including nausea, diarrhea, and constipation, which tend to be most noticeable as doses increase. Both medications include a warning label for pancreatitis risk and carry a boxed warning prohibiting use in patients with personal or family history of medullary thyroid carcinoma or MEN-2 syndrome, based on findings from rodent studies of thyroid C-cell tumors.

Cardiovascular Risk Reduction

Cardiovascular disease remains a leading cause of death in American men, accounting for roughly a quarter of male deaths annually per CDC mortality data (CDC).

Statins

The 2019 ACC/AHA guideline on primary prevention recommends considering statin therapy in adults aged 40-75 with LDL-C of 70-189 mg/dL and an estimated 10-year ASCVD risk of 7.5% or higher (ACC/AHA, 2019). Commonly prescribed options include:

• Atorvastatin 10-80 mg daily (high-intensity: 40-80 mg)
• Rosuvastatin 5-40 mg daily (high-intensity: 20-40 mg)
• Pravastatin 40-80 mg daily (moderate-intensity; sometimes preferred with certain HIV antiretrovirals)

The JUPITER trial (N=17,802) found that rosuvastatin 20 mg reduced first major cardiovascular events by 44% in participants with LDL-C below 130 mg/dL but elevated hsCRP (NEJM, 2008).

Antihypertensives

Stage 1 hypertension is generally defined as a systolic of 130-139 mmHg or diastolic of 80-89 mmHg. For men with stage 2 hypertension (systolic at or above 140) or diabetes, common first-line choices include:

• ACE inhibitors (lisinopril 10-40 mg daily)
• ARBs (losartan 50-100 mg daily)
• Thiazide diuretics (chlorthalidone 12.5-25 mg daily)
• Calcium channel blockers (amlodipine 5-10 mg daily)

Low-Dose Aspirin

The 2022 USPSTF update recommends against initiating aspirin for primary prevention in adults aged 60 and older, since bleeding risk tends to outweigh benefit in that group. Men aged 40-59 with a 10-year ASCVD risk of 10% or greater may still be reasonable candidates, and the decision should be individualized with a physician, per current preventive-medicine guidance. Men already on aspirin for secondary prevention after a prior cardiovascular event should not stop without talking to their cardiologist.

Erectile Dysfunction: PDE5 Inhibitors and Beyond

The Massachusetts Male Aging Study (N=1,290 men aged 40-70) found a combined prevalence of complete, moderate, and minimal erectile dysfunction of roughly half of participants, according to widely cited epidemiological survey data. Prevalence rises with age, diabetes, and cardiovascular disease.

First-Line: Oral PDE5 Inhibitors

The four approved PDE5 inhibitors work by blocking the enzyme that breaks down cyclic GMP, supporting smooth muscle relaxation in the corpus cavernosum. They do not cause erections without sexual stimulation.

Tadalafil 5 mg daily is the only PDE5 inhibitor also FDA-approved for lower urinary tract symptoms from BPH, which makes it a two-for-one option in men with both conditions.

Second-Line and Combination Options

Men who do not respond to oral PDE5 inhibitors at an adequate dose and enough attempts may be candidates for:

• Intraurethral alprostadil (MUSE): a 125-1,000 mcg pellet, with a labeled response rate reported around 40% per product labeling
• Intracavernosal injection therapy (Trimix / Bimix): combined alprostadil, phentolamine, and papaverine; response rates are generally higher than intraurethral therapy in men who did not respond to oral agents
• Vacuum erection devices (non-prescription, often co-prescribed)
• Penile prosthesis (surgical; reserved for refractory cases)

Testosterone normalization often improves PDE5 inhibitor response in hypogonadal men, which is one reason both conditions are commonly evaluated together.

Androgenic Conditions: BPH and Male-Pattern Hair Loss

Benign Prostatic Hyperplasia (BPH)

BPH becomes common with age, affecting a large share of men in their 50s and the majority by their 80s, according to general urologic health resources. Prescription options include:

• Alpha-blockers (tamsulosin 0.4 mg daily): relax smooth muscle in the prostate and bladder neck; symptom relief within 1-2 weeks, but no effect on prostate volume
• 5-alpha reductase inhibitors (finasteride 5 mg daily or dutasteride 0.5 mg daily): shrink prostate volume over 6-12 months; most effective in larger prostates
• Combination therapy: the MTOPS trial (N=3,047) found that combination alpha-blocker plus finasteride therapy reduced clinical progression of BPH substantially more than either drug alone, according to widely cited urology trial data

Male-Pattern Hair Loss (Androgenetic Alopecia)

Finasteride 1 mg daily (Propecia) inhibits type II 5-alpha reductase, reducing scalp and serum DHT by roughly 70%. In clinical trials of finasteride 1 mg for androgenetic alopecia, most treated men maintained or increased hair count at two years compared with a minority on placebo; the exact percentages reported vary by study and should be confirmed against the primary literature before being quoted as a specific figure.

Minoxidil 5% topical solution, or low-dose oral minoxidil (around 1-2.5 mg daily), is commonly added as a second agent. Small trials of low-dose oral minoxidil have shown measurable increases in hair density over roughly six months; the size of the effect varies by study and dose, so a single precise percentage should not be treated as universal.

Persistent sexual side effects after stopping finasteride, sometimes called post-finasteride syndrome, are reported in a small minority of men. Estimates of how common this is vary widely and remain debated in the literature, partly because of under-reporting and partly because causality is hard to establish in observational reports. Men considering finasteride should be told this uncertainty exists rather than given a single confident number.

Metabolic Health: Prediabetes, Insulin Resistance, and Type 2 Diabetes

Metformin

Metformin (typically 500-2,000 mg daily in divided doses) is first-line for type 2 diabetes under current ADA standards of care. The Diabetes Prevention Program (N=3,234) found that metformin reduced progression from prediabetes to diabetes by 31% over roughly three years, most notably in adults under 60 with a BMI above 35 (NEJM, 2002). The ADA's standards of care describe metformin as worth considering for adults with prediabetes, particularly younger patients with a higher BMI and women with a history of gestational diabetes (ADA Standards). Men with a BMI above 35 and fasting glucose in the prediabetic range are reasonable candidates for a conversation about off-label metformin, with renal function monitored.

SGLT2 Inhibitors and GLP-1 Agonists in Diabetes

Men with type 2 diabetes and established or high cardiovascular risk often benefit from adding an SGLT2 inhibitor (empagliflozin 10-25 mg daily, dapagliflozin 10 mg daily) to metformin. The EMPA-REG OUTCOME trial (N=7,020) found empagliflozin reduced cardiovascular death by 38% relative to placebo in this population (NEJM, 2015).

Who Should Not Use These Medications

Every drug class above carries contraindications that matter more in men over 40:

• TRT: active prostate cancer, untreated severe BPH with urinary retention, hematocrit above roughly 54%, or unstable heart failure
• PDE5 inhibitors: concurrent use of nitrates in any form; combining the two can cause dangerous hypotension
• GLP-1 agonists: personal or family history of medullary thyroid carcinoma or MEN-2 syndrome
• Statins: active liver disease or unexplained persistent transaminase elevation; some formulations interact with grapefruit
• Finasteride: not recommended for men actively trying to conceive in the near term without discussing it with a prescriber first, since the drug is present in semen

How to Prioritize: A Decision Framework for Men Over 40

When multiple conditions are present simultaneously, the order in which medications are started becomes relevant. The following framework can help guide a discussion with your prescriber but should not replace that conversation.

Step 1, Screen first. Order a morning fasting panel: total testosterone (before 10 AM), lipid panel, fasting glucose and HbA1c, PSA, CBC, and a comprehensive metabolic panel. Calculate 10-year ASCVD risk.

Step 2, Address cardiovascular risk before anything else that is elective. If 10-year ASCVD risk is 7.5% or higher and LDL is above 70, a statin conversation comes first. Blood pressure at or above 130/80 warrants at least lifestyle counseling; at or above 140/90, pharmacotherapy is usually discussed. Exception: a man with a recent cardiovascular event and significant obesity may have GLP-1 therapy prioritized alongside cardiovascular medication, since the SELECT trial data suggest cardiovascular benefit from the GLP-1 itself in that population.

Step 3, Address metabolic disease next. If HbA1c is 5.7-6.4%, a conversation about off-label metformin, and about a GLP-1 if BMI is above 27, is reasonable. An HbA1c of 6.5% or higher requires formal diabetes management, not an off-label workaround.

Step 4, Address hormonal deficiency after metabolic and cardiovascular issues are stable. Weight loss and improved metabolic control can raise testosterone on their own in men with obesity-related low testosterone, so retesting after meaningful weight loss is often worthwhile before starting TRT. If total testosterone remains below 300 ng/dL on two morning draws with symptoms, TRT is appropriate; formulation choice depends on fertility intent, lifestyle, and how the man tolerates injections versus daily application. Exception: a man actively trying to conceive should discuss hCG or nasal testosterone instead of injectable or gel TRT, or defer TRT until fertility plans are settled.

Step 5, Address sexual function once cardiovascular and hormonal status are reasonably controlled. Start with sildenafil 50 mg or tadalafil 5 mg daily. Give each dose several attempts before concluding it has failed, and confirm there is no nitrate use before prescribing.

Step 6, Address androgenic conditions last, since they are rarely urgent. BPH symptoms that are bothersome (not just present) warrant a tamsulosin trial first. Hair loss concerns can be addressed with finasteride plus topical minoxidil, understanding the uncertainty around long-term sexual side effects described above.

What changes the sequence: active symptoms of urinary retention, a PSA that is rising rapidly, chest pain or new cardiovascular symptoms, or a hematocrit already above the safe range on entry all move a condition ahead of this default order and warrant prompt evaluation rather than following the sequence as written.

Monitoring Schedule Summary